Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients

A single dose of bevacizumab reduced the density of angiopoietin-2-positive vessels while improving the infiltration of CD4+ T and CD8+ T cells, and mature dendritic cells in patients with primary triple-negative breast cancer. Our findings provide a rationale for including bevacizumab during neoadj...

Full description

Saved in:
Bibliographic Details
Published inNPJ precision oncology Vol. 5; no. 1; p. 62
Main Authors Boucher, Yves, Kumar, Ashwin S., Posada, Jessica M., Gjini, Evisa, Pfaff, Kathleen, Lipschitz, Mikel, Lako, Ana, Duda, Dan G., Rodig, Scott J., Hodi, F. Stephen, Jain, Rakesh K.
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 29.06.2021
Nature Publishing Group
Nature Portfolio
Subjects
631/67/1347
692/4028/67/580
Breast cancer
Brief Communication
Cancer Research
Dendritic cells
Gene Therapy
Human Genetics
Immunotherapy
Internal Medicine
Medicine
Medicine & Public Health
Monoclonal antibodies
Oncology
Targeted cancer therapy
Online AccessGet full text

Cover

More Information
Summary:A single dose of bevacizumab reduced the density of angiopoietin-2-positive vessels while improving the infiltration of CD4+ T and CD8+ T cells, and mature dendritic cells in patients with primary triple-negative breast cancer. Our findings provide a rationale for including bevacizumab during neoadjuvant treatment to enhance the efficacy of immune checkpoint blockers in this disease.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2397-768X
2397-768X
DOI:10.1038/s41698-021-00197-w